{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:14:58Z","timestamp":1783030498866,"version":"3.54.6"},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0093","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T08:06:11Z","timestamp":1683101171000},"source":"Crossref","is-referenced-by-count":4,"title":["Antibody-drug conjugates as a targeted therapeutic approach across entities in oncology"],"prefix":"10.3238","author":[{"given":"Florian","family":"Lordick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"B\u00fcch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"10.3238\/arztebl.m2023.0093_ref1","doi-asserted-by":"crossref","unstructured":"K\u00f6hler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495\u20137","DOI":"10.1038\/256495a0"},{"key":"10.3238\/arztebl.m2023.0093_ref2","doi-asserted-by":"crossref","unstructured":"Verhoeyen M, Milstein C, Winter G: Reshaping human antibodies: grafting an antilysozyme activity. Science 1988; 239: 1534\u20136","DOI":"10.1126\/science.2451287"},{"key":"10.3238\/arztebl.m2023.0093_ref3","doi-asserted-by":"crossref","unstructured":"Staudacher AH, Brown MP: Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 2017; 117: 1736\u201342","DOI":"10.1038\/bjc.2017.367"},{"key":"10.3238\/arztebl.m2023.0093_ref4","doi-asserted-by":"crossref","unstructured":"Petersdorf S, Kopecky K, Stuart RK, et al.: Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: 790","DOI":"10.1182\/blood.V114.22.790.790"},{"key":"10.3238\/arztebl.m2023.0093_ref5","doi-asserted-by":"crossref","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, et al.: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2019; 104: 113\u20139","DOI":"10.3324\/haematol.2018.188888"},{"key":"10.3238\/arztebl.m2023.0093_ref6","doi-asserted-by":"crossref","unstructured":"Hills RK, Castaigne S, Appelbaum FR, et al.: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15: 986\u201396","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"10.3238\/arztebl.m2023.0093_ref7","doi-asserted-by":"crossref","unstructured":"Haubner S, Perna F, K\u00f6hnke T, et al.: Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 2019; 33: 64\u201374","DOI":"10.1038\/s41375-018-0180-3"},{"key":"10.3238\/arztebl.m2023.0093_ref8","doi-asserted-by":"crossref","unstructured":"Richardson PG, Corbacioglu S: Veno-occlusive disease\/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J\u00a02020; 10: 29","DOI":"10.1038\/s41408-020-0286-5"},{"key":"10.3238\/arztebl.m2023.0093_ref9","doi-asserted-by":"crossref","unstructured":"Katz J, Janik JE, Younes A: Brentuximab vedotin (SGN-35). Clin Cancer Res 2011; 17: 6428\u201336","DOI":"10.1158\/1078-0432.CCR-11-0488"},{"key":"10.3238\/arztebl.m2023.0093_ref10","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Walewski J, Nademanee A, et al.: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018; 132: 2639\u201342","DOI":"10.1182\/blood-2018-07-861641"},{"key":"10.3238\/arztebl.m2023.0093_ref11","doi-asserted-by":"crossref","unstructured":"Ansell SM, Radford J, Connors JM, et al.: Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2018s Lymphoma. N Engl J Med 2022; 387: 310\u201320","DOI":"10.1056\/NEJMoa2206125"},{"key":"10.3238\/arztebl.m2023.0093_ref12","unstructured":"Horwitz S, O\u2018Connor OA, Pro B, et al.: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet\u00a02019; 393: 229\u201340"},{"key":"10.3238\/arztebl.m2023.0093_ref13","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al.: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016; 375: 740\u201353","DOI":"10.1056\/NEJMoa1509277"},{"key":"10.3238\/arztebl.m2023.0093_ref14","doi-asserted-by":"crossref","unstructured":"Young RM, Shaffer AL, Phelan JD, Staudt LM: B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015; 52: 77\u201385","DOI":"10.1053\/j.seminhematol.2015.01.008"},{"key":"10.3238\/arztebl.m2023.0093_ref15","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al.: Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38: 155\u201365","DOI":"10.1200\/JCO.19.00172"},{"key":"10.3238\/arztebl.m2023.0093_ref16","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Sehn LH, et al.: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022; 386: 351\u201363","DOI":"10.1056\/NEJMoa2115304"},{"key":"10.3238\/arztebl.m2023.0093_ref17","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A, et al.: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207\u201321","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"10.3238\/arztebl.m2023.0093_ref18","doi-asserted-by":"crossref","unstructured":"Wahab A, Rafae A, Mushtaq K, et al.: Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol 2021; 11: 678634","DOI":"10.3389\/fonc.2021.678634"},{"key":"10.3238\/arztebl.m2023.0093_ref19","doi-asserted-by":"crossref","unstructured":"Verma S, Miles D, Gianni L, et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783\u201391","DOI":"10.1056\/NEJMoa1209124"},{"key":"10.3238\/arztebl.m2023.0093_ref20","doi-asserted-by":"crossref","unstructured":"Minckwitz G von, Huang C-S, Mano MS, et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617\u201328","DOI":"10.1056\/NEJMoa1814017"},{"key":"10.3238\/arztebl.m2023.0093_ref21","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, et al.: Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022; 386: 1143\u201354","DOI":"10.1056\/NEJMoa2115022"},{"key":"10.3238\/arztebl.m2023.0093_ref22","doi-asserted-by":"crossref","unstructured":"Modi S, Saura C, Yamashita T, et al.: Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382: 610\u201321","DOI":"10.1056\/NEJMoa1914510"},{"key":"10.3238\/arztebl.m2023.0093_ref23","doi-asserted-by":"crossref","unstructured":"Modi S, Jacot W, Yamashita T, et al.: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022; 387: 9\u201320.","DOI":"10.1056\/NEJMoa2203690"},{"key":"10.3238\/arztebl.m2023.0093_ref24","doi-asserted-by":"crossref","unstructured":"Jerusalem G, Park YH, Hurvitz SA, et al.: Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer Discov 2022; 12: 2754\u201362.","DOI":"10.1158\/2159-8290.CD-22-0837"},{"key":"10.3238\/arztebl.m2023.0093_ref25","doi-asserted-by":"crossref","unstructured":"Shitara K, Bang Y-J, Iwasa S, et al.: Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020; 382: 2419\u201330.","DOI":"10.1056\/NEJMoa2004413"},{"key":"10.3238\/arztebl.m2023.0093_ref26","doi-asserted-by":"crossref","unstructured":"Siena S, Di Bartolomeo M, Raghav K, et al.: Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22: 779\u201389.","DOI":"10.1016\/S1470-2045(21)00086-3"},{"key":"10.3238\/arztebl.m2023.0093_ref27","doi-asserted-by":"crossref","unstructured":"Li BT, Smit EF, Goto Y, et al.: Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022; 386: 241\u201351.","DOI":"10.1056\/NEJMoa2112431"},{"key":"10.3238\/arztebl.m2023.0093_ref28","doi-asserted-by":"crossref","unstructured":"Tarantino P, Modi S, Tolaney SM, et al.: Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol 2021; 7: 1873\u201381.","DOI":"10.1001\/jamaoncol.2021.3595"},{"key":"10.3238\/arztebl.m2023.0093_ref29","doi-asserted-by":"crossref","unstructured":"Starodub AN, Ocean AJ, Shah MA, et al.: First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 2015; 21: 3870\u20138.","DOI":"10.1158\/1078-0432.CCR-14-3321"},{"key":"10.3238\/arztebl.m2023.0093_ref30","doi-asserted-by":"crossref","unstructured":"Bardia A, Tolaney SM, Punie K, et al.: Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 1148\u201356.","DOI":"10.1016\/j.annonc.2021.06.002"},{"key":"10.3238\/arztebl.m2023.0093_ref31","doi-asserted-by":"crossref","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al.: Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021; 384: 1529\u201341.","DOI":"10.1056\/NEJMoa2028485"},{"key":"10.3238\/arztebl.m2023.0093_ref32","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al.: TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021; 39: 2474\u201385.","DOI":"10.1200\/JCO.20.03489"},{"key":"10.3238\/arztebl.m2023.0093_ref33","doi-asserted-by":"crossref","unstructured":"McGregor BA, Sonpavde G: Enfortumab vedotin, a fully human monoclonal antibody against nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial carcinoma. Expert Opin Investig Drugs 2019; 28: 821\u20136.","DOI":"10.1080\/13543784.2019.1667332"},{"key":"10.3238\/arztebl.m2023.0093_ref34","doi-asserted-by":"crossref","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al.: Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021; 384: 1125\u201335.","DOI":"10.1056\/NEJMoa2035807"},{"key":"10.3238\/arztebl.m2023.0093_ref35","doi-asserted-by":"crossref","unstructured":"Schettini F, Barbao P, Bras\u00f3-Maristany F, et al.: Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open 2021; 6: 100102.","DOI":"10.1016\/j.esmoop.2021.100102"},{"key":"10.3238\/arztebl.m2023.0093_ref36","doi-asserted-by":"crossref","unstructured":"Hull A, Li Y, Bartholomeusz D, et al.: Preliminary development and testing of C595 radioimmunoconjugates for targeting MUC1 cancer epitopes in pancreatic ductal adenocarcinoma. Cells 2022; 11:2983.","DOI":"10.3390\/cells11192983"},{"key":"10.3238\/arztebl.m2023.0093_ref37","doi-asserted-by":"crossref","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, et al.: Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 2021; 12: 3528.","DOI":"10.1038\/s41467-021-23793-7"},{"key":"10.3238\/arztebl.m2023.0093_ref38","doi-asserted-by":"crossref","unstructured":"Bauzon M, Drake PM, Barfield RM, Cornali BM, Rupniewski I, Rabuka D: Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 2019; 8: e1565859.","DOI":"10.1080\/2162402X.2019.1565859"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T08:06:24Z","timestamp":1683101184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0093","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}